In 2005, when Medicare Part D was newly anticipated, a consortium of organizations and businesses from the kidney community banded together to figure out how the Medicare Prescription Drug Plans would impact Medicare beneficiaries with kidney disease. The National Kidney Foundation has been managing this Web site with yearly updates based on the initial findings of this consortium. Thank you to the original Initiative partners:
Abbott Laboratories, American Association of Kidney Patients, Inc., American Kidney Fund, American Nephrology Nurses’ Association, The American Society of Nephrology, Amgen, Astellas Pharma US, Inc., Centers for Medicare & Medicaid Services, Central Florida Kidney Center, Inc., DaVita, Inc., DaVita Patient Citizens, The ESRD Network of New York, Fresenius Medical Care North America, Gambro Healthcare US, Genzyme Corporation, Kidney Care Partners, National Kidney Foundation, Inc. (Council of Nephrology Nurses and Technicians of the National Kidney Foundation, Council of Nephrology of Social Workers of the National Kidney Foundation, Council on Renal Nutrition of the National Kidney Foundation), National Minority Health Month Foundation, National Renal Administrators Association, Novartis Pharmaceuticals Corporation, People Like Us, National Kidney Foundation, Pfizer Inc., Pharmaceutical Research and Manufacturers of America, PKD Foundation, Renal Care Group, Inc., The Renal Network, Inc., Renal Physicians Association, Renal Support Network, Roche Pharmaceuticals, Sigma-Tau Pharmaceuticals, Inc., Social Security Administration, Transplant News, The Transplant Pharmacy Coalition, UnitedHealth Group/Ovations, Washington Hospital Center, Wyeth Pharmaceuticals.
*These organizations are assisting in the planning, development, and implementation of this initiative.